First-line chemotherapy with liposomal doxorubicin plus cyclofosfamide in metastatic breast cancer: a case report of early and prolonged response.

Abstract

The treatment choice for metastatic breast cancer should consider the appropriate balance between efficacy and toxicity of the therapy. We discuss a clinical case with an early response and prolonged to liposomal anthracyclines-based chemotherapy, without cardiotoxicity, enhancing the evidence of safety of liposomal formulation to prevent heart damage. Moreover, the case seems to be of interest for the role of 18F-FDG-PET in clinical response assessment: an early decrease of the standardized uptake value value, even before conventional imaging evaluation, is highly predictive for prolonged clinical response.

Cite this paper

@article{Riccardi2013FirstlineCW, title={First-line chemotherapy with liposomal doxorubicin plus cyclofosfamide in metastatic breast cancer: a case report of early and prolonged response.}, author={Ferdinando Riccardi and Carmela Mocerino and Carmela Barbato and Francesca Ambrosio and Lucia Festino and Maria Giuseppa Vitale and Giovanna Carrillo and Martino Trunfio and Salvatore Minelli and Giacomo Carten{\`i}}, journal={International journal of immunopathology and pharmacology}, year={2013}, volume={26 3}, pages={773-8} }